Vistagen Hit With Securities Class Actions After Phase 3 Miss as Investors Face March 16 Deadline

Plaintiff firms are recruiting shareholders for lead-plaintiff motions in a Northern District of California case following a steep post-announcement stock drop.

Overview

At least one federal class action has been filed alleging Vistagen and certain executives misled investors about the Phase 3 PALISADE-3 study of fasedienol.
Law firms including Faruqi & Faruqi, Bernstein Liebhard, Levi & Korsinsky, and Rosen are soliciting shareholders to pursue lead-plaintiff roles.
The suits define a class period from April 1, 2024 through December 16, 2025, covering purchases of Vistagen common stock.
Complaints cite Vistagen’s December 17, 2025 disclosure that PALISADE-3 failed its primary SUDS endpoint and showed no treatment differences on secondary measures.
Vistagen’s stock fell from $4.36 on December 16 to $0.86 on December 17, and investors seeking to be lead plaintiffs must file by March 16, 2026.